Status:

TERMINATED

Fludarabine and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Metastatic Kidney Cancer That Cannot Be Removed By Surgery

Lead Sponsor:

OHSU Knight Cancer Institute

Collaborating Sponsors:

National Cancer Institute (NCI)

Conditions:

Kidney Cancer

Eligibility:

All Genders

18-75 years

Phase:

PHASE2

Brief Summary

RATIONALE: Giving low doses of chemotherapy, such as fludarabine, and radiation therapy before a donor stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune sy...

Detailed Description

OBJECTIVES: * Determine the efficacy of nonmyeloablative conditioning comprising fludarabine and total-body irradiation followed by allogeneic hematopoietic stem cell transplantation, in terms of 6-m...

Eligibility Criteria

Inclusion

  • DISEASE CHARACTERISTICS:
  • Histologically confirmed renal cell carcinoma, including 1 of the following subtypes:
  • Clear cell
  • Papillary
  • Medullary
  • Metastatic disease
  • Not amenable to curative surgery
  • No CNS metastases
  • PATIENT CHARACTERISTICS:
  • Performance status
  • Karnofsky 70-100%
  • Life expectancy
  • More than 6 months
  • Hematopoietic
  • Not specified
  • Hepatic
  • Bilirubin \< 2 times upper limit of normal (ULN)
  • AST or ALT \< 4 times ULN
  • Renal
  • Creatinine clearance \> 50 mL/min
  • Cardiovascular
  • LVEF \> 35%
  • No symptomatic congestive heart failure
  • Pulmonary
  • DLCO \> 40% of predicted OR
  • Total lung capacity or FEV\_1 \> 30% of predicted
  • PRIOR CONCURRENT THERAPY:
  • Biologic therapy
  • More than 30 days since prior biologic therapy
  • Chemotherapy
  • More than 30 days since prior chemotherapy
  • Radiotherapy
  • More than 30 days since prior radiotherapy

Exclusion

    Key Trial Info

    Start Date :

    June 1 2005

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    April 1 2006

    Estimated Enrollment :

    1 Patients enrolled

    Trial Details

    Trial ID

    NCT00243009

    Start Date

    June 1 2005

    End Date

    April 1 2006

    Last Update

    May 28 2012

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    OHSU Knight Cancer Institute

    Portland, Oregon, United States, 97239-3098